about
The long-term effect of energy restricted diets for treating obesityPosition statement on the role of healthcare professionals, patient organizations and industry in European Reference Networks.Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis.Mild cold effects on hunger, food intake, satiety and skin temperature in humans.Glycosphingolipids and insulin resistance.Management of an LCHADD Patient During Pregnancy and High Intensity Exercise.Glycosphingolipids and insulin resistance.Modulation of glycosphingolipid metabolism significantly improves hepatic insulin sensitivity and reverses hepatic steatosis in mice.A long term follow-up study of the development of hip disease in Mucopolysaccharidosis type VI.Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease.New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients.Low HDL cholesterol levels in type I Gaucher disease do not lead to an increased risk of cardiovascular disease.Peripheral Neuropathy, Episodic Rhabdomyolysis, and Hypoparathyroidism in a Patient with Mitochondrial Trifunctional Protein Deficiency.No metabolic effects of mustard allyl-isothiocyanate compared with placebo in men.Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.Osteoporosis in patients with erythropoietic protoporphyria.The role of the clinician in the multi-omics era: are you ready?Adaptive pathway development for Fabry disease: a clinical approach.Editorial commentary: Newborn screening for Fabry disease: Too much too soon?T-lymphocyte subset distribution in human spleen.Classifying the additional morbidities of Gaucher disease.Craniosynostosis affects the majority of mucopolysaccharidosis patients and can contribute to increased intracranial pressureDevelopment and clinical consequences of white matter lesions in Fabry disease: a systematic reviewMucolipidosis type III, a series of adult patientsVery low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemiaBone health in patients with inborn errors of metabolismIssues with European guidelines for phenylketonuriaPredictors of objective cognitive impairment and subjective cognitive complaints in patients with Fabry diseaseSubspecialty training in adult inherited metabolic diseases: a call to action for unmet needsProminent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher diseaseHypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levelsOverweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapyCCL18: a urinary marker of Gaucher cell burden in Gaucher patientsHepatocellular Adenomas and Carcinoma in Asymptomatic, Non-Cirrhotic Type III Glycogen Storage DiseaseImpact of newborn screening for very-long-chain acyl-CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomesOral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real-World DataThe Mini Mental State Examination does not accurately screen for objective cognitive impairment in Fabry DiseaseEducation and training in adult metabolic medicine: Results of an international surveyAntibodies against recombinant alpha-galactosidase A in Fabry disease: Subclass analysis and impact on response to treatment
P50
Q26801142-8E543757-DFF3-4DB5-950C-B7BFD6A34F72Q36503642-EFB06C9B-E3C6-492A-B1A2-8CDE50965858Q36836581-6764818C-8746-40B9-A704-EE3E414DD42EQ37212967-E8840803-6B33-4591-A0F4-C6DC4BF02008Q37419937-2FD8CCF9-81F7-4715-A498-8361AC735CE3Q37707138-AFBCCC49-97C8-413F-9A85-127EF14114E1Q37930554-6640FAC2-4493-4634-A0F7-2B5378C841E2Q38350770-065A5088-27E6-4873-B4C1-E0225930B0C6Q38759316-A1445D1D-0947-4485-824E-962281C11962Q38791409-5D18C059-F7FA-408B-B4AC-767860BD0971Q39066552-45F7236A-AB81-4D18-BD49-BF63439F5538Q40038048-565DED04-0D24-45E4-B85C-5C8176FF6A49Q40049553-5C78E8DF-69D1-45B8-A50C-3D7F81D1D3A6Q43460342-06AB5708-9C1F-48B8-AA18-4B0041CAC227Q47362663-F87414FC-9CCC-4B61-A66A-030B29026816Q47665754-51606F4A-6F58-4BB8-9DCD-B0A5675E507AQ49835278-6AA66F40-066A-4073-9A64-4526E76E7FDFQ49894571-F2C251C9-D1A1-416A-934D-C312632D02C0Q50034214-8E5F18E4-4174-4B31-AC41-A6422D8AB646Q51983220-16D8967F-DDAE-4F31-90DF-D181EEEC54B2Q52809829-C1158A9B-5A25-4B99-90A0-8CC95581AF52Q56261650-07C1C317-C317-4989-B46C-EF0BB42561B3Q57160819-D135A559-9ABD-4A33-A919-8BA667845EA4Q57164826-3B470EA9-5960-4496-BE5D-6D08CAB642B9Q57361267-64766D55-9B26-448D-B35B-026AF7F2234BQ58744635-07893CC6-D02D-42A0-80F4-FFCECA640048Q59444780-5BB09919-7E96-4833-955B-79968C42AB5EQ60907581-35ADC313-7069-429B-9C7A-597297786B7CQ64041133-27284477-086D-4C61-B37D-8C42D0E67B74Q80421291-A75B9EC4-E224-4DEF-A57D-54469447D595Q81388584-DCFA1FEA-0909-4D8F-B67B-901CDD5C0D03Q81469548-569D31C5-73B3-48BA-9BDA-44E237ABA991Q83878822-CC145942-C459-4738-891C-AB29A4679D1AQ86961871-CFC28C1F-FA0B-40A8-92CF-724ABC9E7638Q91563973-C56C7902-F0D4-4517-8724-5E6C5BF6305AQ91824564-09D8E35E-52E7-4472-A2AE-1E10D5F5D1BBQ92487243-3038FFAC-9993-4060-865F-30CD5108F022Q93189506-26E5BEBB-D8F2-4917-AAD5-8DE52424C634Q93352754-E7C0C69C-1605-4669-988E-CFE9EDE6D27D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mirjam Langeveld
@ast
Mirjam Langeveld
@en
Mirjam Langeveld
@es
Mirjam Langeveld
@nl
Mirjam Langeveld
@sl
type
label
Mirjam Langeveld
@ast
Mirjam Langeveld
@en
Mirjam Langeveld
@es
Mirjam Langeveld
@nl
Mirjam Langeveld
@sl
prefLabel
Mirjam Langeveld
@ast
Mirjam Langeveld
@en
Mirjam Langeveld
@es
Mirjam Langeveld
@nl
Mirjam Langeveld
@sl
P106
P31
P496
0000-0002-9934-6831